1-11 of 11
Joseph Jurcic
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions

Andrew H. Lipsky, Brian T. Hill, Allison Winter, Spencer Henick Bachow, Aaron D. Viny, Todd L. Rosenblat, Joseph Jurcic, Nicole Lamanna
Journal: Blood
Blood (2023) 142 (Supplement 1): 3274.
https://doi.org/10.1182/blood-2023-189718
Published: 2023
Journal Articles

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Jorge Cortes, Joseph Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Jr., Brian A. Jonas, Sangmin Lee, Alice Mims, Shyam Ajay Patel, Gary J. Schiller, Jay Yang, Justin M. Watts
Journal: Blood
Blood (2023) 142 (Supplement 1): 2888.
https://doi.org/10.1182/blood-2023-187861
Published: 2023
Journal Articles

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

Tsewang Tashi, Olivier Hermine, Mariana Castells, Mar Guilarte, Vito Sabato, Marcus Maurer, Jens Panse, Ivan Alvarez-Twose, Renata Cabral, Robert Bird, Stéphane Barete, Laurence Bouillet, Maud Hermans, Paul Van Daele, David González-De-Olano, Elizabeth A. Griffiths, Joseph Jurcic, Ingunn Dybedal, Gandhi Laurent Damaj, Philippe Schafhausen, Chiara Elena, Tse-Chieh Teh, Pankit Vachhani, Caroline Labe, Saranya Venugopal, Kevin He, Javier Muñoz-González, Ben Lampson, Robyn Scherber, Prithviraj Bose, Clive Grattan, Thanai Pongdee, Tracy I. George, Cristina Bulai Livideanu
Journal: Blood
Blood (2023) 142 (Supplement 1): 76.
https://doi.org/10.1182/blood-2023-188904
Published: 2023
Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Naval Daver, Joshua F. Zeidner, Junichiro Yuda, Justin M. Watts, Mark J. Levis, Kentaro Fukushima, Takayuki Ikezoe, Yoshiaki Ogawa, Joseph Brandwein, Eunice S. Wang, Yasushi Miyazaki, Timothy Pardee, Naoko Hosono, Takahiro Shima, Hisayuki Yokoyama, Noboru Asada, Joseph Jurcic, Hongliang Cai, Akinobu Watanabe, Matthew Hitron, Emily Brooks, Bo Xu, Jatin Shah, Hagop M. Kantarjian, Harry P. Erba
Journal: Blood
Blood (2023) 142 (Supplement 1): 2911.
https://doi.org/10.1182/blood-2023-179252
Published: 2023
Journal Articles

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Guillermo Garcia-Manero, Olatoyosi Odenike, Shaun Fleming, Gail J. Roboz, Meagan Jacoby, Ilona Cunningham, Karl-Anton Kreuzer, Anoop K Enjeti, Maria R. Baer, Rachel Cook, Joseph Jurcic, Grace Ku, Ying Zhou, David Hoffman, Jalaja Potluri, Jacqueline S. Garcia
Journal: Blood
Blood (2023) 142 (Supplement 1): 1868.
https://doi.org/10.1182/blood-2023-187102
Published: 2023
Journal Articles

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Eunice S. Wang, Brian A. Jonas, Justin M. Watts, Joseph Jurcic, P. Brent Ferrell, Jr., Shira N. Dinner, Jay Yang, Karen Seiter, Alice Mims, William B. Donnellan, William Blum, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 6047.
https://doi.org/10.1182/blood-2023-187584
Published: 2023
Journal Articles

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Clinical Trials & Observations
Renier J. Brentjens, Isabelle Rivière, Jae H. Park, Marco L. Davila, Xiuyan Wang, Jolanta Stefanski, Clare Taylor, Raymond Yeh, Shirley Bartido, Oriana Borquez-Ojeda, Malgorzata Olszewska, Yvette Bernal, Hollie Pegram, Mark Przybylowski, Daniel Hollyman, Yelena Usachenko, Domenick Pirraglia, James Hosey, Elmer Santos, Elizabeth Halton, Peter Maslak, David Scheinberg, Joseph Jurcic, Mark Heaney, Glenn Heller, Mark Frattini, Michel Sadelain
Journal: Blood
Blood (2011) 118 (18): 4817–4828.
https://doi.org/10.1182/blood-2011-04-348540
Published: 2011
Includes: Supplemental data
Journal Articles

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

Clinical Trials & Observations
Peter G. Maslak, Tao Dao, Lee M. Krug, Suzanne Chanel, Tatyana Korontsvit, Victoria Zakhaleva, Ronghua Zhang, Jedd D. Wolchok, Jianda Yuan, Javier Pinilla-Ibarz, Ellin Berman, Mark Weiss, Joseph Jurcic, Mark G. Frattini, David A. Scheinberg
Journal: Blood
Blood (2010) 116 (2): 171–179.
https://doi.org/10.1182/blood-2009-10-250993
Published: 2010
Journal Articles

Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo

Mark G. Frattini, MD, PhD, David Shum, M.S., Kristen M O’Dwyer, M.D., Renier J. Brentjens, MD, PhD, Ray Yeh, Ph.D., Peter Maslak, MD, Mark Lawrence Heaney, MD, PhD, Joseph Jurcic, MD, Hakim Djaballah, Ph.D., Thomas J Kelly, M.D., Ph.D.
Journal: Blood
Blood (2008) 112 (11): 2668.
https://doi.org/10.1182/blood.V112.11.2668.2668
Published: 2008
Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Has Comparable Activity but Appears To Be Better Tolerated Than Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Nicole Lamanna, MD, Matt Kalaycio, MD, Peter Maslak, MD, Mark L. Heaney, MD, PhD, Renier Brentjens, MD, PhD, Joseph Jurcic, MD, Emily Biederman, Alison N. Gencarelli, RN, Katherine S. Panageas, PhD, David A. Scheinberg, MD, PhD, Mark A. Weiss, MD
Journal: Blood
Blood (2005) 106 (11): 2127.
https://doi.org/10.1182/blood.V106.11.2127.2127
Published: 2005
Journal Articles

Pentostatin and Cyclophosphamide with or without Rituximab Has Significant Activity in Patients with Previously Treated Chronic Lymphocytic Leukemia and Other Low Grade Lymphoid Neoplasms.

Nicole Lamanna, MD, Matt Kalaycio, MD, Peter Maslak, MD, Joseph Jurcic, MD, David A. Scheinberg, MD, PhD, Alison N. Gencarelli, RN, Denise Horgan, Mark A. Weiss, MD
Journal: Blood
Blood (2004) 104 (11): 3484.
https://doi.org/10.1182/blood.V104.11.3484.3484
Published: 2004